When a startup says it raised $228 million, most readers picture a company with $228 million of new equity. On November 18, Hone Health announced a round where $28 million is equity and $200 million is something else: money from General Catalyst that pays for sales and marketing and is repaid from the revenue the new customers bring in.
That structure says as much about the longevity clinic business as the headline figure does. In this deep dive we explain how customer value financing works, compare Hone with the testing-first and pre-launch models around it, set out the federal rules on testosterone, menopause hormone therapy, peptides and exosomes that sit under its growth plan, and lay out what investors and operators should check before copying the model.
The financing assumes patients keep paying. The regulators decide which products they can keep buying.
In This Deep Dive
- Why this matters now
- What actually happened
- The obvious read versus the deeper signal
- Category map and taxonomy
- Evidence Ladder
- What FDA, DEA and HHS will ask
- Capital flows and bottom-up economics
- The HealthTech Investor's Signal
- Counter-thesis
- Forward Intelligence
- The Bottom Line for Digital Health Operators and Growth Investors
Why this matters now
Longevity and hormone clinics sell a subscription to ongoing care: testing, a physician relationship and prescriptions. That revenue is predictable once a patient is acquired, but acquiring the patient costs money up front. General Catalyst's argument is that using equity to fund that cost is expensive and dilutive, and that sales and marketing spend deserves financing matched to its output.
Hone's round is the most prominent healthcare use of the idea so far. Alam told Fortune that General Catalyst only offers the deal to companies whose patients stay at a steady rate, that he can call each month and ask for $10 million, and that the arrangement has no recourse and no covenants restricting other fundraising. If retention is what the structure rewards, retention becomes the number to watch.
The timing matters too. Hone says it has treated more than 200,000 patients, up from the 55,000 it reported in January 2025, and it is adding a physician-supervised peptide program while publicly launching a concierge tier that includes exosome and stem cell therapies. The financing is being deployed into categories where federal policy has moved several times in the past two years.
Certainty: (A) round structure, investors and plans from the Hone release; (A) CVF mechanics from General Catalyst; (A) Alam's statements as reported by Fortune; (B) our reading that retention is the key variable, because Alam says retention is the criterion for the deal.
What actually happened
- The round: Hone Health announced $228 million on November 18 in New York. The Series A extension of $28 million was led by MarcyPen Capital Partners, with Pentland Ventures, Kinship Ventures (co-founded by Gwyneth Paltrow), Hanwha, Gannet Capital, humbition, Comma Capital and ID Ventures participating. General Catalyst's Customer Value Fund supplied $200 million of growth financing. Total equity funding is $65 million.
- The disclosure: MarcyPen has been a partner for over two years and also led Hone's $33 million Series A announced in January 2025, a role that had not been disclosed before. Fortune notes MarcyPen formed in 2024 when Marcy Venture Partners merged with the investment arm of Pendulum Holdings.
- The plan: Hone says the money will go to advanced diagnostics (full-body MRI, DEXA scans, coronary CT angiography and gut microbiome analysis), a physician-supervised peptide program for eligible patients "where legally available and clinically appropriate," and clinical trial infrastructure. Alam said most of the equity will go to AI that lets one physician handle problems that would normally send a patient to several specialists.
- The scale: Hone says it has treated more than 200,000 patients, administered 750,000 tests and processed 25 million health markers. Treatment areas are testosterone replacement therapy, menopause hormone therapy, weight management, peptides, thyroid, heart health and sexual health. Alam told Fortune Hone passed $100 million in recurring revenue last year; that figure is a company statement.
- Hone Black: The concierge membership has run in stealth for a year and is launching publicly. It pairs testing of more than 1,600 health markers with a dedicated physician team. Treatment options span prescription medications, supplements, peptides and lifestyle guidance, plus exosome and stem cell therapies. Alam called it a test bed for treatments that may later reach the main product.
Certainty: (A) round, plan and scale figures from the Hone release; (A) the monthly draw, recourse and revenue statements as reported by Fortune, attributed to Alam; revenue and patient numbers are company statements.

The obvious read versus the deeper signal
The obvious read: A celebrity-backed longevity company raised a huge round, and the money will go to marketing and new treatments. On this reading the story is about hype and valuation, and the right response is to wait and see whether the clinic business scales.
The deeper signal: The more important change is how growth is paid for. Only $28 million of the round is equity. The other $200 million finances customer acquisition and is repaid only from the revenue those customers produce, up to a cap. That separates the cost of buying customers from the cost of building the product, and it changes who bears the risk: General Catalyst says it owns the downside if the spend does not pan out. The structure works for a business with steady retention and works against one without it. It also means Hone's pace is tied to how many patients it can acquire and keep in categories that regulators are still adjusting.
Certainty: (B) evidence-based interpretation; the CVF contract terms for Hone are not public beyond Alam's description and GC's general description of the strategy.
Historical playbook
Revenue-based and customer-financed growth is not new in software. General Catalyst argues that over the last decade subscription models became pervasive, that companies finance each customer's lifetime value from their own balance sheet, and that this makes fast growth consume cash. Its Customer Value strategy applies asset-style financing to that spend. TechCrunch reported that GC's fund has also provided $1 billion to Grammarly in May 2025 and $1 billion to Beckham-backed supplement brand IM8 in July 2026, which it called essentially loans with unusual repayment terms.
Hone is the first prominent healthcare name we found using the structure at this scale. Direct-to-consumer health has a mixed record on retention, which is why the disclosure matters: the financing assumes cohorts that behave like subscriptions. The 2025 Series B at Function Health, which raised $298 million at a $2.5 billion valuation, shows the other path, equity at a high valuation for a testing membership priced at $365 a year.











